<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><meta http-equiv="Content-Language" content="en" /><title>Verbatim report of proceedings - Veterinary medicinal products - Wednesday, 2 May 2001</title><meta name="title" content="Verbatim report of proceedings - Veterinary medicinal products - Wednesday, 2 May 2001" /><meta name="language" content="en" /><meta name="robots" content="index, follow, noodp, noydir, notranslate" /><meta name="copyright" content="© European Union, 2001 - Source: European Parliament" /><meta name="available" content="02-05-2001" /><meta name="sipade-leg" content="5" /><meta name="sipade-type" content="CRE" /><meta property="og:title" content="Verbatim report of proceedings - Veterinary medicinal products - Wednesday, 2 May 2001" /><meta property="og:image" content="https://www.europarl.europa.eu/website/common/img/icon/sharelogo_facebook.jpg" /><link rel="canonical" href="https://www.europarl.europa.eu/doceo/document/CRE-5-2001-05-02-ITM-015_EN.html" /><link href="/doceo/data/css/style_common.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_common_print.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_sipade.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_activities.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/common_sides.css" type="text/css" rel="stylesheet" /><link href="/doceo/data/css/style_sipade_oj_sched.css" type="text/css" rel="stylesheet" />
<script src="/doceo/data/js/overlib.js" type="text/javascript"> </script>
<script src="/doceo/data/js/swap_images.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade.js" type="text/javascript"> </script>
<script src="/doceo/data/js/jquery-1.4.4.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade-OJ-SYN.js" type="text/javascript"> </script><!--ATI analytics script--><script type="text/javascript" data-tracker-name="ATInternet" defer data-value="/website/webanalytics/ati-doceo.js" src="//www.europarl.europa.eu/website/privacy-policy/privacy-policy.js" ></script></head><body bgcolor="#FFFFFF"><div id="overDiv" style="position:absolute; visibility:hidden; z-index:1000;"> </div><a name="top"></a><table cellpadding="0" cellspacing="0" border="0" width="100%"><tr><td><div id="header_sides" class="new">
<a href="/portal/en"><img alt="Go back to the Europarl portal" title="Go back to the Europarl portal" src="/doceo/data/img/EP_logo_neg_EN.png" /></a><h3 class="ep_hidden">Choisissez la langue de votre document :</h3><ul class="language_select">
            <li class="bg" title="bg - български">bg - български</li>
            <li><a title="es - español" class="es on" href="/doceo/document/CRE-5-2001-05-02-ITM-015_ES.html">es - español</a></li>
            <li class="cs" title="cs - čeština">cs - čeština</li>
            <li><a title="da - dansk" class="da on" href="/doceo/document/CRE-5-2001-05-02-ITM-015_DA.html">da - dansk</a></li>
            <li><a title="de - Deutsch" class="de on" href="/doceo/document/CRE-5-2001-05-02-ITM-015_DE.html">de - Deutsch</a></li>
            <li class="et" title="et - eesti keel">et - eesti keel</li>
            <li><a title="el - ελληνικά" class="el on" href="/doceo/document/CRE-5-2001-05-02-ITM-015_EL.html">el - ελληνικά</a></li>
            <li class="en selected" title="en - English">en - English<span> (Selected)</span></li>
            <li><a title="fr - français" class="fr on" href="/doceo/document/CRE-5-2001-05-02-ITM-015_FR.html">fr - français</a></li>
            <li class="ga" title="ga - Gaeilge">ga - Gaeilge</li>
            <li class="hr" title="hr - hrvatski">hr - hrvatski</li>
            <li><a title="it - italiano" class="it on" href="/doceo/document/CRE-5-2001-05-02-ITM-015_IT.html">it - italiano</a></li>
            <li class="lv" title="lv - latviešu valoda">lv - latviešu valoda</li>
            <li class="lt" title="lt - lietuvių kalba">lt - lietuvių kalba</li>
            <li class="hu" title="hu - magyar">hu - magyar</li>
            <li class="mt" title="mt - Malti">mt - Malti</li>
            <li><a title="nl - Nederlands" class="nl on" href="/doceo/document/CRE-5-2001-05-02-ITM-015_NL.html">nl - Nederlands</a></li>
            <li class="pl" title="pl - polski">pl - polski</li>
            <li><a title="pt - português" class="pt on" href="/doceo/document/CRE-5-2001-05-02-ITM-015_PT.html">pt - português</a></li>
            <li class="ro" title="ro - română">ro - română</li>
            <li class="sk" title="sk - slovenčina">sk - slovenčina</li>
            <li class="sl" title="sl - slovenščina">sl - slovenščina</li>
            <li><a title="fi - suomi" class="fi on" href="/doceo/document/CRE-5-2001-05-02-ITM-015_FI.html">fi - suomi</a></li>
            <li><a title="sv - svenska" class="sv on" href="/doceo/document/CRE-5-2001-05-02-ITM-015_SV.html">sv - svenska</a></li>
        </ul></div></td></tr><tr><td style="padding:10px;"><table width="100%" border="0" cellspacing="0" cellpadding="0"><tr><td><table border="0" align="left" cellpadding="0" cellspacing="0"><tr><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-5-2001-05-02-TOC_EN.html"><img src="/doceo/data/img/navi_index.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-5-2001-05-02-TOC_EN.html" title="Index">Index</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-5-2001-05-02-ITM-014_EN.html"><img src="/doceo/data/img/navi_previous.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-5-2001-05-02-ITM-014_EN.html" title="Previous">Previous</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin_invisible"><tr><td valign="middle"> Next </td><td><img src="/doceo/data/img/navi_next_grey.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-5-2001-05-02_EN.html"><img src="/doceo/data/img/navi_moredetails.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-5-2001-05-02_EN.html" title="Full text">Full text</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td></tr><tr><td><img src="/doceo/data/img/spacer.gif" width="10" height="15" alt="" /></td></tr></table></td></tr></table><table width="100%" border="0" cellpadding="5" cellspacing="0" class="doc_box_header">
<tr>
<td align="left" valign="top" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="title_TA">Verbatim report of proceedings</td><td valign="top" align="right" style="background-image:url(/doceo/data/img/gradient_blue.gif)"></td>
</tr>
<tr>
<td class="doc_title" align="left" valign="top" bgcolor="#F5F5F5">Wednesday, 2 May 2001 - Brussels</td>
<td class="doc_title" align="right" valign="top" bgcolor="#F5F5F5">OJ edition</td></tr></table><br />
<table width="100%" border="0" cellpadding="0" cellspacing="0" class="doc_box_header" style="padding-bottom:5px"><tr valign="top"><td>
<table width="100%" border="0" cellpadding="5" cellspacing="0"><tr valign="top" style="padding-bottom:0px;padding-left:5px;padding-right:5px;padding-top:5px"><td align="left" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="doc_title"><img src="/doceo/data/img/arrow_title_doc.gif" width="8" height="14" border="0" align="absmiddle" alt="" /> 15. Veterinary medicinal products</td></tr></table>
<a name="3-197"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1106.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">President.</span></span>   – The next item is the report (<a href="/doceo/document/A-5-2001-0119_EN.html">A5-0119/2001</a>) by Mrs Doyle, on behalf of the Committee on the Environment, Public Health and Consumer Policy, on the Commission communication to the Council and the European Parliament on availability of veterinary medicinal products [<a href="https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&amp;lg=EN&amp;type_doc=COMfinal&amp;an_doc=2000&amp;nu_doc=0806">COM(2000) 806</a> – C5-0105/2001 – <a href="https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&amp;reference=2001/2054(COS)">2001/2054(COS)</a>]. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-198"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4382.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Doyle (PPE-DE), </span></span>  <span class="italic">rapporteur.</span> – Mr President, I welcome the Commissioner to the House. On welfare, therapeutic and economic grounds, it is essential that European veterinarians have access to the fullest possible range of veterinary medicines to treat all food-producing animals, while at the same time keeping consumer health protection at the top of all our agendas.</p>
<p class="contents">Requirements for the placing of veterinary medicinal products on the market have been harmonised since the early 1980s when Council Directive 81/851 was adopted. A series of availability problem have arisen, compromising animals health and welfare across species. There is a need for urgent short-term solutions as well as for a broad review of all the legislation involved. This is what the Commission proposes and I fully endorse it. No veterinary medicinal product can be used in food-producing animals unless maximum residue limits, MRLs, are set up for its active substances. A recent evaluation of the EU product licensing procedures observed, and I quote, "significant concern in the veterinary sector about the decreased availability of established medicinal products for food-producing animals as a result of the introduction of the MRL requirements."</p>
<p class="contents">The issue was brought to a head at the end of 1999 with the expiry of a transitional period for fixing MRLs for established drugs. In many cases, the lack of adequate economic return has been an important factor in the failure of sponsoring companies to commit the necessary resources to generating the data necessary to satisfy EU regulatory requirements for fixing MRLs. Many pharmaceutical companies have been spending up to 25% of the research budget in defending their products.</p>
<p class="contents">In its communications the Commission announces a number of short-term measures, the extrapolation of MRLs, and medium-term actions such as incentives for industry, more flexible rules for the use of products and the revision of the existing legal instruments. They announced these measures to increase the availability of products. These actions are to be welcomed and, in particular, the extrapolation of MRLs between species that could help to maintain on the market many products intended for minor species.</p>
<p class="contents">The MRL problem gives rise to greatest concern in these minor food-producing species, such as horses, goats, rabbits, fish, bees – minor in terms of their economic importance for the pharmaceutical companies, hence their lack of defence of the various veterinary products required. But major species have also been affected. In my own country, Ireland, there is no legal local anaesthetic to use on cattle at this point in time. Every country can point to a major species where a drug has been taken off the market, not because it is not available somewhere in Europe, but because there has not been a marketing authorisation for that particular Member State. Hence, the point I am making – and the Commission also shares this view – is that we need a pan-European system whereby a product authorised properly in one Member State can be used throughout the EU.</p>
<p class="contents">I would also encourage Member States to develop this system as quickly as possible, because it will be part of the short-term resolution of the crisis, and I use that word advisedly, that exists at the moment with the availability of veterinary medicines on the ground.</p>
<p class="contents">Many new Member States have been pressing the Commission for some time to deal with the availability problem, taking particular account of the unique situation of horses. None of the other minor food-producing species I have mentioned exhibit similar features as the length of the life span, sections of the industry not being oriented towards food production, high monetary value of individual animals and the recreational and sentimental value.</p>
<p class="contents">A further complication is that three DGs are involved in all of this: ENTR, SANCO and indeed AGRI. In December 1999, DG SANCO proposed to allow the veterinary use of substances without MRLs in horses, provided records of treatment are kept and horses do not enter into the food chain before six months after use. Provisions relating to the equine passport were modified through Decision 2000/68 but it subsequently ran into legal problems.</p>
<p class="contents">Passports are now obligatory for all horses and contain a new annex for recording of veterinary treatments. Directive 81/851 and Council Regulation No 2377/90 are however still to be amended to allow such use.</p>
<p class="contents">I am very aware of the concerns of the horse industry, particularly the thoroughbred industry, and I do not have to remind the Commissioner that if a full and up-to-date range of therapies is not available, there is a real risk that foreign investment in stud and training establishments throughout Europe will be lost to third countries. Having said that, it cannot be ruled out that any horse could enter the food chain at the end of its useful life and therefore safeguards are necessary to cover this aspect, as I have already mentioned.</p>
<p class="contents">In conclusion, I would urge the Commission to ensure that as quickly as possible we have a short-term resolution to the crisis for minor food-producing species in relation to the availability of state-of-art veterinary medicines. It is a welfare issue, it is a therapeutic issue, it is an economic issue, and it is in every Member State of the EU. We urge the Commission to move as quickly as possible to amend the necessary regulation, to allow extrapolation, the use of passports for horses and to resolve the problem. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-199"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/2231.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">McKenna (Verts/ALE).</span></span>   – Like the rapporteur, I come from a country where we do not eat horses – people ride them but they do not eat them, the same as in the UK – and therefore I find it difficult to comprehend. But I suppose there are other traditions in Europe, like eating <span class="italic">foie gras</span>, which is distasteful, because you also have to consider how the animal is reared, in humane conditions or not, how is the animal transported etc. With <span class="italic">foie gras</span> it is a much more cruel exercise and much more distasteful than eating horses because, at least in most cases, the horses have a better life than the unfortunate geese.</p>
<p class="contents">But it is clear that in some European countries horses are produced for human consumption – in the Benelux countries, France and Italy, there is quite a large consumption of horsemeat – and we have to take this into account. As far as I can see, no distinction has been made, either by the Member States, or by the EU legislator, between horses raised for the purpose of meat production and horses raised for recreational purposes. In relation to the access to medical and veterinary products for horses, we also have to take into account the whole issue of animal welfare problems. When we look at horses that have been used for recreational purposes that end up going into the human food chain, it is essential that a precautionary approach is taken to ensure that public health and consumer protection take priority. Even though horses are not initially reared for human consumption, they do end up in the human food chain.</p>
<p class="contents">It is extremely important we have viable and traceable means to ensure that farmers observe any preslaughter waiting-time periods, in particular concerning recreational horses entering the chain for human consumption. It is an extremely important issue because although it will not affect people in Ireland and the UK – because we do not eat horses – it will in other countries. It is important that there is a balance between animal welfare and the need for consumer protection. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-200"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/doceo/data/img/photo_generic.gif" align="right" width="50" height="63" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Liikanen,</span></span>   <span class="italic">Commission.</span> – On behalf of the Commission, I would like to thank Mrs Doyle and the Committee on the Environment, Public Health and Consumer Policy for this report.</p>
<p class="contents">There are many different perspectives to be reconciled. Unfortunately, no satisfactory solution has yet been found. The communication aimed to present the Commission's view on the problem of veterinary medicine availability and noted with satisfaction that the committee and the rapporteur share the general concerns of the Commission on this issue. This communication clearly does not bring a direct solution; however, it outlines the options for further action in both the long and short term.</p>
<p class="contents">It is important to point out that the current veterinary and pharmaceutical legislation provides a framework designed to ensure, amongst other things, the optimal protection of consumer health. This legislation is currently being reviewed. This review will provide a timed framework to further address the availability problem for all animal species concerned in a global manner. Any proposal for change to ease the access to the market of veterinary and pharmaceutical products, or to facilitate the use of certain medicines by veterinarians, will be in the interest of animal health and welfare. However, it goes without saying that any of these proposals will have to be compatible with the objective of consumer health protection. With this end in mind, I am cooperating with colleagues, Mr Byrne, in particular, and I expect the legislative proposal to be finalised within a few months. This will allow an in-depth discussion with the European Parliament and the Council on all relevant matters. Obviously, these legislative changes will take some time.</p>
<p class="contents">The Commission has therefore also announced its approval of the principle of extrapolating maximum residue limits established for some species to other species. Such an exploration would only be possible under certain conditions. While we recognise that extrapolating maximum residue limits cannot be a global solution, we believe that it can represent a practical improvement of the situation, particularly in the short term. However, it also raises the complex technical issues, in particular the link with the possible illegal use of certain substances. Thus, a need for appropriate analytical methods of control will have to be considered. I am hoping that the further work in close cooperation between the European Parliament, the Council and the Commission will lead to a balanced solution, offering a framework for genuine benefit to animal health, while maintaining a high level of consumer protection. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-201"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1106.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">President.</span></span>   –<span class="bold"> </span>Thank you, Commissioner Liikanen.</p>
<p class="contents">The debate is closed.</p>
<p class="contents">The vote will take place tomorrow at 11 a.m. <a href="#def_1_1" name="ref_1_1"><sup>(1)</sup></a></p>
<p class="contents"><span class="italic">(The sitting was closed at 11.10 p.m.) </span></p></td><td width="16"> </td></tr></table>
<table width="100%" border="0" cellpadding="5" cellspacing="0" class="contents">
<tr><td width="70" align="center" valign="top"> </td><td width="5"> </td><td align="left" valign="top">
<p><table border="0" cellspacing="0" cellpadding="0" class="inpage_annotation_doc"><tr><td><img src="/doceo/data/img/hr.gif" width="180" height="1" alt="" /><table border="0" cellspacing="0" cellpadding="0">
<tr valign="top" style="padding-top:5px"><td width="20"><a name="def_1_1" href="#ref_1_1">(1)</a></td><td> <span class="italic">Agenda for next sitting</span>: see Minutes</td></tr></table></td></tr></table></p></td></tr></table></td></tr></table><table width="100%" border="0" cellspacing="0" cellpadding="5"><tr class="footerdocwin"><td></td><td align="right"><a target="_blank" href="/legal-notice/en">Legal notice</a> - <a target="_blank" href="/privacy-policy/en">Privacy policy</a></td></tr></table></td></tr></table></body></html>
